Table 1 ATLAS surveillance reporting Performance Measures

1. STI Testing Rate

Proportion of clients tested for STIs (CT, NG, TV, syphilis and HIV) during the reporting period

2. STI Testing Coverage

Proportion of current clients tested for STIs at least once in a 12-month period

3. STI test positivity

Proportion of clients with at least one positive STI test in a 12-month period

4. Completeness of STI Testing

Proportion of clients with a positive CT and/or NG and/or TV result also tested for syphilis and HIV within 30 days of date of initial specimen collection

5. STI Treatment Interval

Time (days) from date of positive STI (CT, NG, TV) test to date of treatment

6. STI Retesting Rate

Proportion of clients retested at approximately three months (60 to 120 days) following treatment for an initial positive STI (CT/NG/TV) result

7. STI Repeat Positivity Rate

Proportion of clients retested at approximately three months (60 to 120 days) after treatment for an initial positive CT/NG result and who retested positive for CT/NG at this time

8. Hepatitis B Virus (HBV) Testing Rate

Proportion of clients receiving an HBV test. Among those testing negative, the proportion who subsequently received one or more dose of vaccination.

9. Hepatitis C (HCV) Testing Rate

Proportion of clients receiving an HCV antibody test and among those testing positive, the proportion then tested for RNA or viral load.

10. HCV Treatment Uptake

Proportion of HCV RNA positive clients prescribed Direct Acting Antiviral (DAA) treatment

11. HCV Sustained Virological Response

Proportion of clients who, after having been prescribed DAA treatment, achieve an undetectable viral load

12. HPV Screening Rate

Proportion of female clients screened for human papillomavirus in line with national guidelines